vs
Side-by-side financial comparison of CARRIAGE SERVICES INC (CSV) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $105.5M, roughly 1.6× CARRIAGE SERVICES INC). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 8.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 1.0%).
Jardine Cycle & Carriage Limited is the investment holding company of Jardines in Southeast Asia. It is currently 75% held by the conglomerate.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CSV vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $105.5M | $168.4M |
| Net Profit | $12.3M | — |
| Gross Margin | 34.8% | — |
| Operating Margin | 23.3% | 50.6% |
| Net Margin | 11.6% | — |
| Revenue YoY | 8.0% | 143.7% |
| Net Profit YoY | 24.5% | — |
| EPS (diluted) | $0.76 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $105.5M | $168.4M | ||
| Q3 25 | $102.7M | $87.3M | ||
| Q2 25 | $102.1M | $82.4M | ||
| Q1 25 | $107.1M | $65.0M | ||
| Q4 24 | $97.7M | $69.1M | ||
| Q3 24 | $100.7M | $51.6M | ||
| Q2 24 | $102.3M | $73.8M | ||
| Q1 24 | $103.5M | $137.7M |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $6.6M | $-31.3M | ||
| Q2 25 | $11.7M | $-12.7M | ||
| Q1 25 | $20.9M | $-40.5M | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.9M | $-29.5M | ||
| Q2 24 | $6.3M | $-61.9M | ||
| Q1 24 | $7.0M | $61.0M |
| Q4 25 | 34.8% | — | ||
| Q3 25 | 35.3% | — | ||
| Q2 25 | 35.2% | — | ||
| Q1 25 | 35.3% | — | ||
| Q4 24 | 34.4% | — | ||
| Q3 24 | 35.2% | — | ||
| Q2 24 | 36.2% | — | ||
| Q1 24 | 36.0% | — |
| Q4 25 | 23.3% | 50.6% | ||
| Q3 25 | 17.0% | -11.4% | ||
| Q2 25 | 23.5% | 8.6% | ||
| Q1 25 | 29.5% | -34.0% | ||
| Q4 24 | 21.6% | -6.4% | ||
| Q3 24 | 22.7% | -31.0% | ||
| Q2 24 | 18.0% | 3.5% | ||
| Q1 24 | 18.8% | 52.5% |
| Q4 25 | 11.6% | — | ||
| Q3 25 | 6.4% | -35.9% | ||
| Q2 25 | 11.5% | -15.4% | ||
| Q1 25 | 19.5% | -62.2% | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 9.8% | -57.2% | ||
| Q2 24 | 6.1% | -83.9% | ||
| Q1 24 | 6.7% | 44.3% |
| Q4 25 | $0.76 | $0.32 | ||
| Q3 25 | $0.41 | $-0.16 | ||
| Q2 25 | $0.74 | $-0.06 | ||
| Q1 25 | $1.34 | $-0.21 | ||
| Q4 24 | $0.62 | $-0.14 | ||
| Q3 24 | $0.63 | $-0.15 | ||
| Q2 24 | $0.40 | $-0.33 | ||
| Q1 24 | $0.45 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $254.8M | $-302.0M |
| Total Assets | $1.3B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $167.9M | ||
| Q3 25 | $1.2M | $92.4M | ||
| Q2 25 | $1.4M | $86.1M | ||
| Q1 25 | $4.6M | $114.6M | ||
| Q4 24 | $1.2M | $144.8M | ||
| Q3 24 | $1.3M | $144.7M | ||
| Q2 24 | $1.5M | $189.3M | ||
| Q1 24 | $1.7M | $226.6M |
| Q4 25 | $254.8M | $-302.0M | ||
| Q3 25 | $242.1M | $-451.4M | ||
| Q2 25 | $235.4M | $-433.5M | ||
| Q1 25 | $223.1M | $-426.2M | ||
| Q4 24 | $208.6M | $-388.7M | ||
| Q3 24 | $198.1M | $-370.2M | ||
| Q2 24 | $187.9M | $-344.2M | ||
| Q1 24 | $179.6M | $-294.3M |
| Q4 25 | $1.3B | $465.9M | ||
| Q3 25 | $1.3B | $364.0M | ||
| Q2 25 | $1.3B | $347.1M | ||
| Q1 25 | $1.3B | $324.0M | ||
| Q4 24 | $1.3B | $343.8M | ||
| Q3 24 | $1.3B | $314.1M | ||
| Q2 24 | $1.3B | $352.3M | ||
| Q1 24 | $1.3B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.1M | $45.2M |
| Free Cash FlowOCF − Capex | $6.2M | — |
| FCF MarginFCF / Revenue | 5.9% | — |
| Capex IntensityCapex / Revenue | 7.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.15× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.1M | $45.2M | ||
| Q3 25 | $24.7M | $-4.3M | ||
| Q2 25 | $8.1M | $-31.4M | ||
| Q1 25 | $13.8M | $-22.6M | ||
| Q4 24 | $9.3M | $-35.0M | ||
| Q3 24 | $20.9M | $-35.3M | ||
| Q2 24 | $2.2M | $-7.2M | ||
| Q1 24 | $19.7M | $53.8M |
| Q4 25 | $6.2M | — | ||
| Q3 25 | $18.0M | — | ||
| Q2 25 | $5.2M | — | ||
| Q1 25 | $10.6M | — | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | $16.2M | $-35.5M | ||
| Q2 24 | $-1.4M | $-7.3M | ||
| Q1 24 | $16.2M | $53.8M |
| Q4 25 | 5.9% | — | ||
| Q3 25 | 17.5% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 16.1% | -68.7% | ||
| Q2 24 | -1.4% | -9.9% | ||
| Q1 24 | 15.6% | 39.0% |
| Q4 25 | 7.5% | 0.0% | ||
| Q3 25 | 6.5% | 0.0% | ||
| Q2 25 | 2.8% | 0.0% | ||
| Q1 25 | 3.0% | 0.0% | ||
| Q4 24 | 4.5% | 0.0% | ||
| Q3 24 | 4.6% | 0.3% | ||
| Q2 24 | 3.5% | 0.1% | ||
| Q1 24 | 3.4% | 0.1% |
| Q4 25 | 1.15× | — | ||
| Q3 25 | 3.76× | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 2.83× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
